0001628280-20-010229.txt : 20200706 0001628280-20-010229.hdr.sgml : 20200706 20200706201238 ACCESSION NUMBER: 0001628280-20-010229 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200702 FILED AS OF DATE: 20200706 DATE AS OF CHANGE: 20200706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Talasaz AmirAli CENTRAL INDEX KEY: 0001753159 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 201014939 MAIL ADDRESS: STREET 1: 18 ISABELLA AVENUE CITY: ATHERTON STATE: CA ZIP: 94027 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 wf-form4_159408074472014.xml FORM 4 X0306 4 2020-07-02 0 0001576280 Guardant Health, Inc. GH 0001753159 Talasaz AmirAli 505 PENOBSCOT DRIVE REDWOOD CITY CA 94063 1 1 0 0 Chairman, President and COO COMMON STOCK 2020-07-02 4 M 0 54892 4.18 A 2744424 D COMMON STOCK 2020-07-02 4 S 0 9533 83.4829 D 2734891 D COMMON STOCK 2020-07-02 4 S 0 44299 83.9309 D 2690592 D COMMON STOCK 2020-07-02 4 S 0 1060 84.8078 D 2689532 D COMMON STOCK 2020-07-06 4 M 0 20108 4.18 A 2709640 D COMMON STOCK 2020-07-06 4 S 0 15000 83.9924 D 2694640 D COMMON STOCK 2020-07-06 4 S 0 5108 84.40 D 2689532 D COMMON STOCK 737800 I Shares held by Talasaz Investments, L.P. STOCK OPTION (RIGHT TO BUY) 4.18 2020-07-02 4 M 0 54892 0 D 2022-07-13 COMMON STOCK 54892.0 710613 D STOCK OPTION (RIGHT TO BUY) 4.18 2020-07-06 4 M 0 20108 0 D 2022-07-13 COMMON STOCK 20108.0 690505 D These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $82.68 to $83.675, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.68 to $84.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $84.715 to $84.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $83.40 to $84.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. /s/ John Saia, as Attorney-in-Fact for AmirAli Talasaz 2020-07-06